Form 4: Castle Biosciences CEO Derek Maetzold Sells Shares Under 10b5-1 Plan

Castle Biosciences CEO Derek Maetzold sold shares of common stock on March 26, 2025, through various trusts, as part of a pre-arranged Rule 10b5-1 trading plan.

Summary

• On March 26, 2025, Derek J Maetzold, the President and CEO of Castle Biosciences, Inc. (CSTL), reported the sale of company stock.
• The sales were executed under a Rule 10b5-1 trading plan adopted on November 11, 2024.
• Maetzold sold 1,236 shares directly at $20.30 per share.
• Additional shares were sold indirectly through several trusts for which Maetzold serves as trustee or has a beneficial interest.
• These trusts include The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, and several Maetzold 2018 Remainder Trusts.
• The weighted-average sale price for these transactions ranged from $20.01 to $20.72.
• Following the reported transactions, Maetzold directly owns 77,099 shares and indirectly owns shares through various trusts, including 65,025 shares held by The Maetzold Descendants 2020 Trust, 55,372 shares held by Derek Maetzold 2020 Irrevocable Trust, 4,608 shares held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk, 4,605 shares held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold, 4,605 shares held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold, 4,605 shares held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold, 122,866 shares held by DJM Grantor Retained Annuity Trust No. 5, and 26,134 shares held by DJM Grantor Retained Annuity Trust No. 6.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The document simply reports insider selling under a pre-arranged plan, which is a common and legal practice. It doesn't necessarily indicate a negative outlook for the company, but it also doesn't provide any positive signals.

Negatives

• The CEO selling shares, even under a 10b5-1 plan, could be perceived negatively by some investors.

Risks

• Continued sales by the CEO could put downward pressure on the stock price.
• Investor sentiment could be negatively impacted by insider selling.

Industry Context

Insider selling is a common occurrence in publicly traded companies, and the use of 10b5-1 plans allows insiders to sell shares over time without being accused of trading on material non-public information. It's important to consider the context of these sales in relation to the company's overall performance and outlook.

Stakeholder Impact

• Shareholders may react to the news of insider selling, potentially impacting the stock price.

Key Dates

Keywords

Castle Biosciences, CSTL, Derek Maetzold, insider trading, Form 4, Rule 10b5-1, stock sale, trusts